

REDOXINE

Wine stabilization against iron casse and oxidation

CHARACTERISTICS

Thanks to the combination of ascorbic and citric acids, **REDOXINE** instantly protects wine against iron casse. It maintains color and tints of wines by its reducing action.

CHARACTERISTICS	JUSTIFICATION	ADVANTAGES			
Ascorbic acid					
Reducing power	Drop in oxidoreduction potential	 Reduces iron in ferrous state, which then becomes soluble. Prevents iron removal in certain white and rosé wines 			
	Captures dissolved oxygen	Protects color and aromas			
Combined with	Stops	Prevents oxidation of			
SO ₂	polyphenoloxydases' enzyme process	polyphenols, protects color			
Citric acid					
Acidifying agent	Improves preservation of reducing properties of ascorbic acid	Intensifies ascorbic acid action			

Combining the two products allows:

- High protection against all oxidative phenomena and maintenance of the minimum level of oxydoreduction potential in wines, favoring the development of the bouquet.
- One-step operation limiting further wine handling.

APPLICATION RATE

10 to 30 g/hl.

Maximum legal dose according to current European regulations: 100 mg/hL.

INSTRUCTIONS FOR USE

Dilute in 5 times its weight in wine in a non-metallic container. Incorporate away from air during pump over. Do not aerate the wine violently. Always use in combination with SO2.

Precaution for use:

For oenological and specifically professional use. Use according to current regulation.

178/2020 - 1/2





_	-	_			_		_
ъ.	A .	\sim	v	A .	G		
\mathbf{r}	Δ		ж.	Δ	(-	IN	

Fine crystals packaged in 1 kg polyethylene bags.

STORAGE

Full packaging, seal of origin, store away from light in a dry and scent-free, frost protected place. Once open: use quickly.

Information given in this document represents our current knowledge. It is not binding and offered without guarantees since the application conditions are out of our control. It does not release the user from abiding by the legislation and applicable health and safety standards. This document is the property of SOFRALAB and may not be modified without its agreement.

178/2020 - 2/2